Literature DB >> 23489501

Expression profile of microrna-145 in urothelial bladder cancer.

Nelson Dip1, Sabrina T Reis, Miguel Srougi, Marcos F Dall'Oglio, Katia R M Leite.   

Abstract

PURPOSE: Bladder cancer (BC) is the second most common malignancy of the urinary tract, with high mortality. The knowledge of the molecular pathways associated with BC carcinogenesis is crucial to identify new diagnostic and prognostic biomarkers. MicroRNAs (miRNAs) are short non-coding RNA molecules that play important roles in the regulation of gene expression by acting directly on mRNAs. miR-145 has been considered as a tumor suppressor, which targets the c-MYC, MUC-1 and FSCN1 genes. Our aim was to evaluate the expression profile of miR-145 in low-grade non-invasive and high-grade invasive bladder urothelial carcinomas.
MATERIALS AND METHODS: We studied 30 specimens of low-grade, non-invasive pTa and 30 of pT2/pT3 high-grade invasive UC obtained by transurethral resection or radical cystectomy, followed over a mean time of 16.1 months. Normal controls were represented by five samples of normal bladder biopsy from patients who underwent retropubic prostatectomy to treat BPH. miRNA extraction and cDNA generation were performed using commercial kits. Analysis was performed by qRT-PCR, and miR-145 expression was calculated using the 2-(▵▵ct) method; we used RNU-43 and RNU-48 as endogenous controls.
RESULTS: miR-145 was under-expressed in 73.3% and 86.7% of pTa and pT2/pT3, respectively, with expression means of 1.61 for the former and 0.66 for the last. There were no significant differences in miR-145 expression and histological grade, tumor stage, angiolymphatic neoplastic invasion and tumor recurrence.
CONCLUSION: miR-145 is under-expressed in low-grade, non-invasive and high-grade invasive urothelial bladder carcinoma and may play an important role in the carcinogenesis pathway, being an interesting candidate diagnostic marker.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23489501     DOI: 10.1590/S1677-5538.IBJU.2013.01.12

Source DB:  PubMed          Journal:  Int Braz J Urol        ISSN: 1677-5538            Impact factor:   1.541


  9 in total

Review 1.  MicroRNAs: Key Players in Bladder Cancer.

Authors:  Qi Li; Helei Wang; Hourong Peng; Qiuping Huang; Ting Huyan; Qingsheng Huang; Hui Yang; Junling Shi
Journal:  Mol Diagn Ther       Date:  2019-10       Impact factor: 4.074

2.  Role of STAT3 and FOXO1 in the Divergent Therapeutic Responses of Non-metastatic and Metastatic Bladder Cancer Cells to miR-145.

Authors:  Guosong Jiang; Chao Huang; Jingxia Li; Haishan Huang; Honglei Jin; Junlan Zhu; Xue-Ru Wu; Chuanshu Huang
Journal:  Mol Cancer Ther       Date:  2017-02-21       Impact factor: 6.261

Review 3.  MicroRNA-145: a potent tumour suppressor that regulates multiple cellular pathways.

Authors:  Shi-Yun Cui; Rui Wang; Long-Bang Chen
Journal:  J Cell Mol Med       Date:  2014-08-15       Impact factor: 5.310

Review 4.  Novel non invasive diagnostic strategies in bladder cancer.

Authors:  Anamaria Truta; Tudor Adrian Hodor Popon; George Saraci; Liviu Ghervan; Ioan Victor Pop
Journal:  Clujul Med       Date:  2016-04-15

Review 5.  Bladder cancer: Micro RNAs as biomolecules for prognostication and surveillance.

Authors:  Nilay Mitash; Swasti Tiwari; Shalini Agnihotri; Anil Mandhani
Journal:  Indian J Urol       Date:  2017 Apr-Jun

6.  Urinary MicroRNAs as Potential Markers for Non-Invasive Diagnosis of Bladder Cancer.

Authors:  Kati Erdmann; Karsten Salomo; Anna Klimova; Ulrike Heberling; Andrea Lohse-Fischer; Romy Fuehrer; Christian Thomas; Ingo Roeder; Michael Froehner; Manfred P Wirth; Susanne Fuessel
Journal:  Int J Mol Sci       Date:  2020-05-27       Impact factor: 5.923

7.  Berberine inhibited metastasis through miR-145/MMP16 axis in vitro.

Authors:  Jie Li; Songlin Zhang; Lei Wu; Meili Pei; Yu Jiang
Journal:  J Ovarian Res       Date:  2021-01-06       Impact factor: 4.234

8.  microRNA-99a inhibiting cell proliferation, migration and invasion by targeting fibroblast growth factor receptor 3 in bladder cancer.

Authors:  Deyao Wu; Yunfeng Zhou; Huixing Pan; Jian Zhou; Yuanfeng Fan; Ping Qu
Journal:  Oncol Lett       Date:  2014-02-12       Impact factor: 2.967

Review 9.  Current Advances in Coptidis Rhizoma for Gastrointestinal and Other Cancers.

Authors:  Luying He; Zhangfeng Zhong; Man Chen; Qilian Liang; Yitao Wang; Wen Tan
Journal:  Front Pharmacol       Date:  2022-01-03       Impact factor: 5.988

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.